Skip to content
The Peptide Effect
Comparison

Thymosin Alpha-1 vs Thymosin Beta-4

Thymosin alpha-1 and thymosin beta-4 are both derived from the thymus gland but serve fundamentally different biological roles. Thymosin alpha-1 (marketed as Zadaxin) is a 28-amino-acid immunomodulatory peptide that enhances T-cell maturation, dendritic cell activation, and antiviral/antitumor immune responses — it is approved in over 35 countries for hepatitis B and used as an immune adjuvant. Thymosin beta-4 is a 43-amino-acid peptide that drives tissue repair through actin sequestration, cell migration, and angiogenesis, making it the primary healing peptide of the thymosin family. Despite sharing a name origin, they target entirely different systems.

Side-by-side comparison diagram of Thymosin Alpha-1 and Thymosin Beta-4 mechanisms of action
Conceptual comparison — not to scale

Head-to-Head Comparison

CriteriaThymosin Alpha-1Thymosin Beta-4
Primary functionImmunomodulation — T-cell maturation, dendritic cell activationTissue repair — actin regulation, cell migration, angiogenesis
Amino acid length28 amino acids (acetylated at N-terminus)43 amino acids (the most abundant intracellular peptide)
Mechanism of actionActivates toll-like receptors (TLR9), enhances MHC class I expression, stimulates NK cellsSequesters G-actin monomers, promotes cell migration and blood vessel formation
Primary target systemImmune system — adaptive and innate immunityMusculoskeletal and cardiovascular — tissue regeneration
Regulatory statusApproved as Zadaxin in 35+ countries (hepatitis B/C); orphan drug status in USNo regulatory approval; available as research peptide (TB-500 is the active fragment)
Route of administrationSubcutaneous injection (1.6 mg standard dose)Subcutaneous or intramuscular injection
Typical dosage1.6 mg, 2x weekly (approved dose); up to 3.2 mg in some protocols2.0–5.0 mg, 2x weekly (as TB-500 fragment)
Hepatitis B/C treatmentYes — approved indication in multiple countries; improves viral clearanceNot used for viral infections
Cardiac repairIndirect — may support immune-mediated cardiac recoveryDirect — promotes cardiomyocyte survival, angiogenesis in ischemic heart tissue
Cancer immunotherapy adjuvantYes — studied as immune adjuvant with chemotherapy and checkpoint inhibitorsNot used in oncology; theoretical concern about promoting angiogenesis near tumors
Wound/injury healingIndirect — supports immune component of healingPrimary use case — accelerates healing of tendons, muscles, and wounds
Safety profileExcellent — extensive human safety data from approved use worldwidePreclinical — extensive animal safety data, limited formal human trial data

When to Choose Each

Choose Thymosin Alpha-1

Immune system enhancement, chronic hepatitis B/C, cancer immunotherapy adjunct, post-infection immune recovery, immunocompromised patients, vaccine response optimization

Choose Thymosin Beta-4

Musculoskeletal injury healing, cardiac repair post-MI, tendon and ligament recovery, wound healing, systemic tissue regeneration, sports injury recovery

Verdict

Thymosin alpha-1 and thymosin beta-4 are not interchangeable — they serve completely different purposes despite their shared thymic origin. Thymosin alpha-1 is the choice for immune enhancement: chronic infections (hepatitis B/C, HIV adjunct), immune deficiency, cancer immunotherapy support, and post-viral immune recovery. Thymosin beta-4 (or its fragment TB-500) is the choice for tissue repair: musculoskeletal injuries, cardiac damage, wound healing, and systemic recovery from physical trauma. Thymosin alpha-1 has the significant advantage of regulatory approval and extensive human clinical data, while thymosin beta-4 remains a research peptide with strong preclinical evidence.

References

  1. Thymosin alpha 1 — a peptide immune modulator with a broad range of clinical applications (2014) — PubMed
  2. Thymosin beta-4 promotes angiogenesis, wound healing, and hair follicle development (2006) — PubMed
  3. Thymalfasin (thymosin alpha-1) in the treatment of hepatitis B and C (2007) — PubMed
  4. Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival, and cardiac repair (2004) — PubMed
  5. Thymosin alpha-1 as an immunomodulatory agent for treatment of cancer and hepatitis (2017) — PubMed
  6. Actin sequestering protein thymosin beta-4 in inflammation and tissue remodeling (2016) — PubMed

Frequently Asked Questions

Are thymosin alpha-1 and thymosin beta-4 related?
They share a name because both were originally isolated from thymus gland extracts (thymosin fraction 5) in the 1960s-70s by Allan Goldstein's lab. However, they are encoded by completely different genes, have different amino acid sequences, and serve different biological functions. Thymosin alpha-1 is primarily involved in immune regulation while thymosin beta-4 is the major actin-sequestering peptide involved in cell motility and tissue repair. The shared name is historical, not functional.
Can thymosin alpha-1 and thymosin beta-4 be used together?
Yes, they can be combined as they target different systems (immune vs. tissue repair). This combination may be particularly relevant in scenarios requiring both immune support and tissue healing — such as post-surgical recovery in immunocompromised patients or chronic infections with associated tissue damage. There are no known negative interactions between the two peptides.
Why is thymosin alpha-1 approved but thymosin beta-4 is not?
Thymosin alpha-1 (Zadaxin) went through formal clinical trials for hepatitis B treatment and was approved in over 35 countries starting in the late 1990s, largely driven by SciClone Pharmaceuticals. Thymosin beta-4 has not undergone the same regulatory pathway — its primary commercial interest has been in veterinary applications (equine healing) and as a research peptide. RegeneRx Biopharmaceuticals conducted some clinical trials for wound healing (RGN-259 eye drops) but full approval has not been achieved.
What is TB-500 and how does it relate to thymosin beta-4?
TB-500 is the commonly available research peptide that represents the active region of full-length thymosin beta-4. Specifically, TB-500 contains the 17-amino-acid actin-binding domain (residues 17-23, with the key sequence LKKTETQ) that is responsible for most of thymosin beta-4's healing properties. Most commercially available "thymosin beta-4" products are actually TB-500. The terms are often used interchangeably in the peptide community, though they are technically distinct.
How do thymosin alpha-1 and thymosin beta-4 compare in cost and availability?
Thymosin alpha-1 is the more accessible of the two because of its pharmaceutical-grade production as Zadaxin in countries where it is approved. Brand-name Zadaxin typically costs several hundred dollars per month. Compounding pharmacy versions in the US are more affordable, typically $100 to $300 per month. Thymosin beta-4 (as TB-500) is available through research peptide suppliers at approximately $60 to $120 per month. The full-length thymosin beta-4 protein is significantly more expensive to produce than the TB-500 fragment. Regulatory status and availability vary by jurisdiction, so consulting a healthcare provider about legal access in your location is recommended.

Explore next